人乳头状瘤病毒及脱落细胞在宫颈癌筛查中的应用
|
摘要
宫颈癌是女性生殖系统最常见的恶性肿瘤之一,是发展中国家女性因癌死亡的主要原因,我国宫颈癌患病率和死亡率占世界的1/3,且宫颈癌的发病呈年轻化趋势。人乳头瘤病毒(HPV)与宫颈癌的发生密切相关,持续性高危型HPV感染是宫颈癌发生、发展的首要原因。宫颈癌的早期诊断、早期治疗是改善宫颈癌预后的关键。应用脱落细胞联合HPV检测能够有效提高宫颈癌筛查的准确性,有效降低漏诊率,对宫颈癌筛查具有重要的临床意义。
Cervical cancer is the most common malignant tumors in women and the leading cause of cancer death in developing country, the morbidity and mortality of cervical cancer in China accounted for 1/3 in the world, the incidence of cervical cancer is younger. Human papillomavirus(HPV) is closely related to the occurrence of cervical cancer, persistent high-risk HPV infection is the primary cause of cervical cancer occurrence and development. Early diagnosis and early treatment of cervical cancer is the key to improve the prognosis of cervical cancer. Application of exfoliated cells combined with HPV detection can effectively improve the accuracy of cervical cancer screening and reduce the rate of missed diagnosis, which is of great significance of cervical cancer screening.
Cervical cancer is the most common malignant tumors in women and the leading cause of cancer death in developing country, the morbidity and mortality of cervical cancer in China accounted for 1/3 in the world, the incidence of cervical cancer is younger. Human papillomavirus(HPV) is closely related to the occurrence of cervical cancer, persistent high-risk HPV infection is the primary cause of cervical cancer occurrence and development. Early diagnosis and early treatment of cervical cancer is the key to improve the prognosis of cervical cancer. Application of exfoliated cells combined with HPV detection can effectively improve the accuracy of cervical cancer screening and reduce the rate of missed diagnosis, which is of great significance of cervical cancer screening.
引文
[1]王华,陈亚宝,叶丽华,等.应用支链DNA技术检测人乳头瘤病毒E6/E7m RNA在宫颈疾病筛查中的价值[J].中华临床医师杂志:电子版,2011,5(15):4362-4366.
[2]Magnani C,Gillio TA,De Marco L,et al.Results and costevaluation of triage with high risk HPV test in cervical cancerscreening A pilot study in Piedmont(North-West Italy)[J].Epidemiol Prevent,2012,36(2):88-94.
[3]李国慧.人类乳头状瘤病毒载量与宫颈病变关系研究进展[J].中国医药,2013,8(7):1039-1040.
[4]Massad LS,Einstein MH,Huh WK,et al.2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors[J].Obstet Gynecol,2013,121(4):829-846.
[5]任守凤.宫颈上皮内瘤变及宫颈癌与人乳头瘤病毒感染的关系探讨[J].中国实用医药,2011,6(26):61-62.
[6]徐萍,方筠,应春妹.高危型HPVDNA检测与细胞学检查用于宫颈疾病诊疗筛查的结果分析[J].检验医学,2016,31(6):516-520.
[7]李新玲,赵敏.HC2HPV(人乳头状瘤病毒)DNA检测与子宫颈癌筛查的相关性分析[J].中国实用医刊,2011,6(34):106-107.
[8]蒲雪.进行液基薄层细胞学联合阴道镜检查对宫颈病变的诊断意义[J].求医问药:学术版,2013,13(5):164.
[9]卢娉霞,邹红,祝先进,等.1 603例女性宫颈脱落细胞HPVDNA检测结果分析[J].福建医科大学学报,2012,46(2):144-145.
[10]Junyangdikul P,Tanchotsrinon W,Chansaenroj J,et al.Clinical prediction based on HPV DNA testing by hybrid capture 2(HC2)in combination with liquid-based cytology(LBC)[J].Asian Pac J Cancer Prev,2013,14(2):903-907.
[11]Du CB,Schroeder ER,Munson E.Clinical laboratory experience with cervista HPV HR as a function of cytological classification:Comparison with retrospective digene HC2 high-risk HPV DNA test data[J].J Clin Microbiol,2013,51(3):1057-1058.
[2]Magnani C,Gillio TA,De Marco L,et al.Results and costevaluation of triage with high risk HPV test in cervical cancerscreening A pilot study in Piedmont(North-West Italy)[J].Epidemiol Prevent,2012,36(2):88-94.
[3]李国慧.人类乳头状瘤病毒载量与宫颈病变关系研究进展[J].中国医药,2013,8(7):1039-1040.
[4]Massad LS,Einstein MH,Huh WK,et al.2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors[J].Obstet Gynecol,2013,121(4):829-846.
[5]任守凤.宫颈上皮内瘤变及宫颈癌与人乳头瘤病毒感染的关系探讨[J].中国实用医药,2011,6(26):61-62.
[6]徐萍,方筠,应春妹.高危型HPVDNA检测与细胞学检查用于宫颈疾病诊疗筛查的结果分析[J].检验医学,2016,31(6):516-520.
[7]李新玲,赵敏.HC2HPV(人乳头状瘤病毒)DNA检测与子宫颈癌筛查的相关性分析[J].中国实用医刊,2011,6(34):106-107.
[8]蒲雪.进行液基薄层细胞学联合阴道镜检查对宫颈病变的诊断意义[J].求医问药:学术版,2013,13(5):164.
[9]卢娉霞,邹红,祝先进,等.1 603例女性宫颈脱落细胞HPVDNA检测结果分析[J].福建医科大学学报,2012,46(2):144-145.
[10]Junyangdikul P,Tanchotsrinon W,Chansaenroj J,et al.Clinical prediction based on HPV DNA testing by hybrid capture 2(HC2)in combination with liquid-based cytology(LBC)[J].Asian Pac J Cancer Prev,2013,14(2):903-907.
[11]Du CB,Schroeder ER,Munson E.Clinical laboratory experience with cervista HPV HR as a function of cytological classification:Comparison with retrospective digene HC2 high-risk HPV DNA test data[J].J Clin Microbiol,2013,51(3):1057-1058.